[A17-58] Tivozanib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 01.02.2018
Project no.:
A17-58
Commission:
Commission awarded on 02.11.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Renal cell carcinoma
Due to a lack of usable study data, an added benefit is neither proven for first-line treatment nor for disease progression after cytokine treatment.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-17 | Tivozanib (renal cell carcinoma) - Addendum to Commission A17-58 | Commission completed |
Federal Joint Committee (G-BA)
2018-04-19 A G-BA decision was published.